Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.

Jurmeister P, Vollbrecht C, Behnke A, Frost N, Arnold A, Treue D, Rückert JC, Neudecker J, Schweizer L, Klauschen F, Horst D, Hummel M, Dietel M, von Laffert M.

Lung Cancer. 2019 Dec;138:43-51. doi: 10.1016/j.lungcan.2019.10.005. Epub 2019 Oct 11.

PMID:
31634654
2.

Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases.

Jurmeister P, Bockmayr M, Seegerer P, Bockmayr T, Treue D, Montavon G, Vollbrecht C, Arnold A, Teichmann D, Bressem K, Schüller U, von Laffert M, Müller KR, Capper D, Klauschen F.

Sci Transl Med. 2019 Sep 11;11(509). pii: eaaw8513. doi: 10.1126/scitranslmed.aaw8513.

PMID:
31511427
3.

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.

Vollbrecht C, Lenze D, Hummel M, Lehmann A, Moebs M, Frost N, Jurmeister P, Schweizer L, Kellner U, Dietel M, von Laffert M.

BMC Cancer. 2018 Nov 22;18(1):1158. doi: 10.1186/s12885-018-5070-6.

4.

Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients.

Vollbrecht C, Lehmann A, Lenze D, Hummel M.

Oncotarget. 2018 Apr 6;9(26):18529-18539. doi: 10.18632/oncotarget.24908. eCollection 2018 Apr 6.

5.

EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.

Fassunke J, Ihle MA, Lenze D, Lehmann A, Hummel M, Vollbrecht C, Penzel R, Volckmar AL, Stenzinger A, Endris V, Jung A, Lehmann U, Zeugner S, Baretton G, Kreipe H, Schirmacher P, Kirchner T, Dietel M, Büttner R, Merkelbach-Bruse S.

Virchows Arch. 2017 Oct;471(4):509-520. doi: 10.1007/s00428-017-2226-8. Epub 2017 Sep 8.

PMID:
28884371
6.

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH.

Oncotarget. 2017 Jun 6;8(23):37502-37510. doi: 10.18632/oncotarget.16398.

7.

Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors.

Walter RF, Vollbrecht C, Christoph D, Werner R, Schmeller J, Flom E, Trakada G, Rapti A, Adamidis V, Hohenforst-Schmidt W, Kollmeier J, Mairinger T, Wohlschlaeger J, Zarogoulidis P, Porpodis K, Schmidt KW, Mairinger FD.

J Cancer. 2016 Oct 25;7(15):2165-2172. eCollection 2016.

8.

ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology.

Walter RF, Werner R, Vollbrecht C, Hager T, Flom E, Christoph DC, Schmeller J, Schmid KW, Wohlschlaeger J, Mairinger FD.

PLoS One. 2016 Nov 1;11(11):e0165181. doi: 10.1371/journal.pone.0165181. eCollection 2016.

9.

Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.

Walter RF, Vollbrecht C, Werner R, Mairinger T, Schmeller J, Flom E, Wohlschlaeger J, Barbetakis N, Paliouras D, Chatzinikolaou F, Adamidis V, Tsakiridis K, Zarogoulidis P, Trakada G, Christoph DC, Schmid KW, Mairinger FD.

J Cancer. 2016 Sep 13;7(13):1915-1925. eCollection 2016.

10.

MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.

Grünewald I, Trautmann M, Busch A, Bauer L, Huss S, Schweinshaupt P, Vollbrecht C, Odenthal M, Quaas A, Büttner R, Meyer MF, Beutner D, Hüttenbrink KB, Wardelmann E, Stenner M, Hartmann W.

Oncotarget. 2016 Nov 15;7(46):75261-75272. doi: 10.18632/oncotarget.12127.

11.

Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.

Walter RF, Mairinger FD, Werner R, Vollbrecht C, Hager T, Schmid KW, Wohlschlaeger J, Christoph DC.

Oncotarget. 2016 Apr 12;7(15):20166-79. doi: 10.18632/oncotarget.7737.

12.

microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.

Walter RF, Vollbrecht C, Werner R, Wohlschlaeger J, Christoph DC, Schmid KW, Mairinger FD.

Oncotarget. 2016 Apr 5;7(14):18713-21. doi: 10.18632/oncotarget.7666.

13.

Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.

Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Schmid KW, Wohlschlaeger J, Mairinger FD.

Br J Cancer. 2015 Dec 22;113(12):1704-11. doi: 10.1038/bjc.2015.397. Epub 2015 Dec 8.

14.

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K, Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F, Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M, Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U, Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC.

J Thorac Oncol. 2015 Jul;10(7):1049-57. doi: 10.1097/JTO.0000000000000570.

15.

Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing.

Vollbrecht C, Mairinger FD, Koitzsch U, Peifer M, Koenig K, Heukamp LC, Crispatzu G, Wilden L, Kreuzer KA, Hallek M, Odenthal M, Herling CD, Buettner R.

PLoS One. 2015 Jun 8;10(6):e0129544. doi: 10.1371/journal.pone.0129544. eCollection 2015.

16.

Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.

Grünewald I, Vollbrecht C, Meinrath J, Meyer MF, Heukamp LC, Drebber U, Quaas A, Beutner D, Hüttenbrink KB, Wardelmann E, Hartmann W, Büttner R, Odenthal M, Stenner M.

Oncotarget. 2015 Jul 20;6(20):18224-37.

17.

Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.

Walter RF, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J, Mairinger FD.

Oncotarget. 2015 Sep 22;6(28):24690-8. doi: 10.18632/oncotarget.3992.

18.

SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString).

Walter RF, Mairinger FD, Werner R, Ting S, Vollbrecht C, Theegarten D, Christoph DC, Zarogoulidis K, Schmid KW, Zarogoulidis P, Wohlschlaeger J.

Future Oncol. 2015;11(7):1027-36. doi: 10.2217/fon.15.18.

PMID:
25804118
19.

MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Walter RF, Mairinger FD, Ting S, Vollbrecht C, Mairinger T, Theegarten D, Christoph DC, Schmid KW, Wohlschlaeger J.

Br J Cancer. 2015 Mar 3;112(5):883-90. doi: 10.1038/bjc.2015.27. Epub 2015 Feb 10.

20.

Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours.

Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Schmid KW, Wohlschlaeger J.

J Cancer. 2014 Aug 1;5(8):646-54. doi: 10.7150/jca.9955. eCollection 2014.

21.

Isothermal multiple displacement amplification: a methodical approach enhancing molecular routine diagnostics of microcarcinomas and small biopsies.

Mairinger FD, Walter RF, Vollbrecht C, Hager T, Worm K, Ting S, Wohlschläger J, Zarogoulidis P, Zarogoulidis K, Schmid KW.

Onco Targets Ther. 2014 Aug 13;7:1441-7. doi: 10.2147/OTT.S65144. eCollection 2014.

22.

Activation of angiogenesis differs strongly between pulmonary carcinoids and neuroendocrine carinomas and is crucial for carcinoid tumourgenesis.

Mairinger FD, Walter RF, Werner R, Christoph DC, Ting S, Vollbrecht C, Zarogoulidis K, Huang H, Li Q, Schmid KW, Wohlschlaeger J, Zarogoulidis P.

J Cancer. 2014 May 15;5(6):465-71. doi: 10.7150/jca.9235. eCollection 2014.

23.

Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.

Mairinger FD, Walter RF, Ting S, Vollbrecht C, Kollmeier J, Griff S, Hager T, Mairinger T, Christoph DC, Theegarten D, Schmid KW, Wohlschlaeger J.

Future Oncol. 2014 May;10(6):995-1005. doi: 10.2217/fon.13.261.

PMID:
24941985
24.

Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study.

Mairinger FD, Ting S, Werner R, Walter RF, Hager T, Vollbrecht C, Christoph D, Worm K, Mairinger T, Sheu-Grabellus SY, Theegarten D, Schmid KW, Wohlschlaeger J.

Mod Pathol. 2014 Dec;27(12):1632-40. doi: 10.1038/modpathol.2014.74. Epub 2014 May 30.

25.

The "COLD-PCR approach" for early and cost-effective detection of tyrosine kinase inhibitor resistance mutations in EGFR-positive non-small cell lung cancer.

Mairinger FD, Vollbrecht C, Streubel A, Roth A, Landt O, Walter HF, Kollmeier J, Mairinger T.

Appl Immunohistochem Mol Morphol. 2014;22(2):114-8. doi: 10.1097/PDM.0b013e31829a638d.

PMID:
24517913
26.

FFPE tissue as a feasible source for gene expression analysis--a comparison of three reference genes and one tumor marker.

Walter RF, Mairinger FD, Wohlschlaeger J, Worm K, Ting S, Vollbrecht C, Schmid KW, Hager T.

Pathol Res Pract. 2013 Dec;209(12):784-9. doi: 10.1016/j.prp.2013.09.007. Epub 2013 Sep 26.

PMID:
24156825
27.

The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Mairinger F, Vollbrecht C, Mairinger T, Popper H.

J Thorac Oncol. 2013 Aug;8(8):e80-2. doi: 10.1097/JTO.0b013e31829b1cf9. No abstract available.

28.

Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues.

Becker K, Vollbrecht C, Koitzsch U, Koenig K, Fassunke J, Huss S, Nuernberg P, Heukamp LC, Buettner R, Odenthal M, Altmueller J, Merkelbach-Bruse S.

J Clin Pathol. 2013 Sep;66(9):803-6. doi: 10.1136/jclinpath-2013-201549. Epub 2013 Apr 25.

PMID:
23618693
29.

Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.

Mairinger F, Vollbrecht C, Halbwedl I, Hatz M, Stacher E, Gülly C, Quehenberger F, Stephan-Falkenau S, Kollmeier J, Roth A, Mairinger T, Popper H.

J Thorac Oncol. 2013 May;8(5):644-53. doi: 10.1097/JTO.0b013e318287c224.

30.

[Molecular pathology of the lungs. New perspectives by next generation sequencing].

Vollbrecht C, König K, Heukamp L, Büttner R, Odenthal M.

Pathologe. 2013 Feb;34(1):16-24. doi: 10.1007/s00292-012-1704-7. Review. German.

PMID:
23389825
31.

[Indications and limitations of fresh frozen sections in the pulmonary apparatus].

Pütz K, Engels M, Vollbrecht C, Heukamp LC, Adam AC, Büttner R.

Pathologe. 2012 Sep;33(5):402-6. doi: 10.1007/s00292-012-1603-y. Review. German.

PMID:
22782501

Supplemental Content

Loading ...
Support Center